This article was originally published in The Gray Sheet
Planned 7% staffcut, about 75 of the firm's 1,093 employees by year-end, relates to an August restructuring to consolidate certain non-marketing functions of the company's McGhan Medical and BioEnterics units. The most recent cuts are in addition to the 85 layoffs that McGhan announced in March and will result in a $2.2 mil. third-quarter charge
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.